Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progen Pharmaceuticals, an Australia-based biotechnology company which is into designing and development of cancer therapeutics, has appointed Sue MacLeman as chief executive officer responsible for the strategic development.
Subscribe to our email newsletter
Progen said that Sue MacLeman has international senior management and leadership experience in product development and commercialisation in the biotechnology and pharmaceutical sector.
Ms MacLeman is also a member of the Pharmaceutical Industry Council (PIC) and Pharmaceutical Industry Working Group (PIWG) and the chair of the Pharmaceutical Industry Development Taskforce (PIDT).
In 1991 she joined the pharmaceutical industry with Schering Plough in the biotechnology business unit. She then went on to work with Amgen and Bristol Myers Squibb Pharmaceuticals in the areas of oncology and infectious diseases medical, marketing, sales management and business development.
In 2002 she took up the position of global vice president for Agenix where she was responsible for the product development of the molecular clot imaging project. From 2004 to 2006 she was the CEO of publicly listed biotechnology investment and management company EQiTX. Most recently Sue was CEO of RNAi therapeutics company Benitec, said the company.
Stuart James, non executive chairman of Progen Pharmaceuticals, said: “The appointment of Sue MacLeman is an important milestone in the strategic development of Progen Pharmaceuticals. Sue brings a wealth of oncology experience and an impressive track record of product development and commercialisation in the biotechnology sector. Sue’s appointment will greatly strengthen the Progen team at this important stage in the company’s development.
“I would like to thank Dr John Chiplin who has been interim CEO and over the next few months a transition plan is in place for John to step back into his Non Executive Board role with Sue coming on board as full time CEO.”
Ms MacLeman said: “I am delighted to be joining the team at Progen Pharmaceuticals. The company is at an exciting stage and I have been impressed both by the calibre of the people and the quality of the science. I look forward to working with the Board and Management Team to create real and sustainable shareholder value.”